Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals director Saira Ramasastry reported new equity awards. She received 1,980 restricted stock units and stock options for 3,772 shares of common stock with an exercise price of 101 per share. Both awards vest on the first anniversary of the grant date, or earlier if fully vested by Mirum’s 2027 annual stockholder meeting. The options expire on June 14, 2036. These are compensation-related grants rather than open-market purchases or sales.
Mirum Pharmaceuticals director William Fairey reported new equity awards consisting of deferred stock units and stock options. He received 1,980 deferred stock units and options for 3,772 shares of common stock at an exercise price of $101.00 per share, all as compensation awards.
The options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service.
Mirum Pharmaceuticals director Laura Brege reported equity awards consisting of deferred stock units and stock options. She received 1,980 deferred stock units, each representing a contingent right to one share of common stock, and 3,772 stock options to buy common stock at an exercise price of $101.00 per share.
Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case will be fully vested by the company’s 2027 annual stockholder meeting. The options expire on June 14, 2036. Vested deferred stock units will be settled in common stock upon a change in control of Mirum or within 60 days after Brege’s separation from service.
Mirum Pharmaceuticals director Patrick J. Heron received new equity awards as part of his compensation. He was granted 1,980 deferred stock units and 3,772 stock options, each option giving the right to buy one share of common stock at an exercise price of $101.00 per share.
The stock options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service. These are grants and not open‑market purchases or sales.
Mirum Pharmaceuticals director Laurent Fischer received new equity awards in the form of deferred stock units and stock options. The filing shows a grant of 1,980 deferred stock units and 3,772 stock options, each tied to Mirum common stock.
The stock options carry an exercise price of $101.00 per share and expire on June 14, 2036. Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case are fully vested by the date of Mirum’s 2027 annual stockholder meeting.
Each deferred stock unit represents a right to receive one share of common stock. Vested deferred stock units will be settled in stock upon the earlier of a change in control of Mirum or within 60 days after Fischer’s separation from service with the company.
GREY MICHAEL G reported acquisition or exercise transactions in this Form 4 filing.
Mirum Pharmaceuticals director Michael G. Grey received new equity compensation awards. On June 15, 2026, he was granted 1,980 restricted stock units, each representing a right to receive one share of common stock, and 3,772 stock options exercisable at $101.00 per share.
Both the RSUs and options are scheduled to vest on the first anniversary of the grant date, but will in any case be fully vested on the date of Mirum’s 2027 annual stockholder meeting. After these grants, Grey directly holds 1,980 RSUs and 3,772 options, with the options expiring on June 14, 2036.
MIRM proposed sale notice filed on 06/17/2026 lists 2,594 shares of Common stock offered for sale through Morgan Stanley Smith Barney LLC. The filing breaks the shares into 1,205 Performance Shares (03/15/2026), 722 Restricted Stock (01/06/2024) and 667 Restricted Stock (07/01/2024).
Mirum Pharmaceuticals, Inc. Chief Financial Officer Eric Bjerkholt exercised stock options and sold shares in the company. On June 9, 2026, he exercised 2,393 Employee Stock Options at an exercise price of $26.49 per share, receiving the same number of common shares. On June 8, 2026, he sold a total of 5,000 common shares in open-market transactions at weighted average prices of $92.84, $93.95 and $95.12, within the disclosed trading ranges. The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 Plan. Following these transactions, Bjerkholt directly owns 47,181 common shares of Mirum Pharmaceuticals.
Mirum Pharmaceuticals President and COO Peter Radovich exercised stock options to acquire 16,988 shares of common stock at $19.19 per share. These options were fully vested at the time of exercise. After the transaction, he directly holds 57,260 shares of Mirum common stock.
Following the exercise, Radovich still holds 48,012 stock options with an exercise price of $19.19 per share, expiring on January 6, 2031. The filing reflects a derivative exercise only, with no open-market share sales reported in this transaction.
MIRM affiliate filed a Form 144 proposing the sale of 5,000 shares of Common Stock. The filing lists the securities as Restricted Stock with an effective date of 09/11/2024.
The filing also reports a prior sale by Eric Bjerkholt of 7,287 shares on 03/16/2026 for $670,242.96.